Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis

Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked to chronic hepat...

Full description

Bibliographic Details
Main Authors: Alex Claveria-Cabello, Leticia Colyn, Iker Uriarte, Maria Ujue Latasa, Maria Arechederra, Jose M. Herranz, Laura Alvarez, Jesus M. Urman, Maria L. Martinez-Chantar, Jesus M. Banales, Bruno Sangro, Krista Rombouts, Julen Oyarzabal, Jose J. G. Marin, Carmen Berasain, Matias A. Avila, Maite G. Fernandez-Barrena
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
liver fibrosis
hepatobiliary carcinogenesis
histone deacetylases
cGMP phosphodiesterase inhibitor
HDAC inhibitor
precision medicine
Online Access:https://www.mdpi.com/2072-6694/12/12/3748

Internet

https://www.mdpi.com/2072-6694/12/12/3748

Similar Items